Stocks Health care CAI
NASDAQ · Health careCaris Life Sciences, Inc. (CAI)
Caris Life Sciences, Inc. brought in $1B of revenue over the twelve months to September 30, 2026. Net income was $96.1M, a net margin of 9.2%. Operating cash flow minus capital spending left $66.9M of free cash flow in fiscal 2025. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about Caris Life Sciences, Inc.
- Net worth
- Caris Life Sciences, Inc. has a market value (market cap) of $6.9B at the latest share price, and shareholders' equity of $639.5M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $812M (+97.0% year on year), with a net loss of $68.1M. Over the 12 months to September 30, 2026: revenue $1B, net income $96.1M.
- Cash flow
- In fiscal 2025 operations brought in $83.2M of cash; after $16.3M of capital spending, free cash flow was $66.9M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Caris Life Sciences, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Caris Life Sciences, Inc. does
Caris Life Sciences, Inc. is registered with the SEC under industry code SIC 8071 (Services-Medical Laboratories). Its shares trade on NASDAQ under the ticker CAI.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $812M | -$68.1M | -$3.22 | $66.9M |
| 2025 | $412.3M | -$281.9M | -$10.66 | -$253.6M |
| 2023 | $306.1M | -$341.4M | -$13.24 | -$298.4M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where CAI ranks in Health care
Latest SEC filings
What Caris Life Sciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Passive stake changed SCHEDULE 13G/A
- November 4, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 27% to $275.4M versus the same quarter last year; diluted EPS $0.05 versus $0.08.
- November 4, 2026
- September 14, 2026
- August 12, 2026Passive stake changed SCHEDULE 13G/A
- August 7, 2026Passive stake changed SCHEDULE 13G/A
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 45% to $263.7M versus the same quarter last year; diluted EPS $0.00 versus -$7.97.
- August 5, 2026
- June 5, 2026
- May 12, 2026Passive stake changed SCHEDULE 13G/A
What is CAI worth? A DCF from its reported cash flow
Insider trades
What the people running Caris Life Sciences, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $27.2M worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 22, 2026 | Denton John RusselSee Remarks | Sold | 7,500 | $238.6K |
| September 17, 2026 | Brille Brian JSee Remarks, Director | Exercised options | 400,000 | $976K |
| September 17, 2026 | Brille Brian JSee Remarks, Director | Sold | 400,000 | $12.1M |
| September 4, 2026 | Spetzler David BaxleyPresident | Exercised options | 250,000 | $610K |
| September 4, 2026 | Spetzler David BaxleyPresident | Sold | 119,212 | $3M |
| September 3, 2026 | Spetzler David BaxleyPresident | Exercised options | 1,000,000 | $2.4M |
| September 3, 2026 | Spetzler David BaxleyPresident | Sold | 393,100 | $9.7M |
| September 3, 2026 | Spetzler David BaxleyPresident | Sold | 84,900 | $2.1M |
Who owns CAI
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| David D. Halbert13G, passive with 1 related filers | 44.1% | August 13, 2025 |
| Fmr LLC13G, passive with 1 related filers | 10.8% | April 7, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 246 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 30,923,878 | +138,293 |
| J. H. Whitney Equity Partners VI, LLC | 11,256,615 | -7,000,000 |
| Coatue Management LLC | 9,819,992 | 0 |
| Braidwell LP | 8,256,032 | +246,585 |
| Sixth Street Partners Management Company, L.P. | 7,327,041 | -7,058,358 |
| PointState Capital LP | 6,828,835 | -531,611 |
| Jpmorgan Chase & Co | 6,558,514 | +3,098,299 |
| BlackRock, Inc. | 5,536,798 | +679,686 |
| Vanguard Portfolio Management LLC | 4,844,431 | +1,085,969 |
| Vanguard Capital Management LLC | 4,280,238 | +951,217 |
| Los Angeles Capital Management LLC | 3,958,531 | +1,668,929 |
| Neuberger Berman Group LLC | 3,590,963 | +377 |
| Orbimed Advisors LLC | 2,806,811 | 0 |
| Bnp Paribas Financial Markets | 2,370,268 | +755,982 |
| Millennium Management LLC | 2,202,647 | +674,891 |
| Mak Capital One LLC | 1,937,229 | new |
| Morgan Stanley | 1,935,531 | +856,114 |
| Clearbridge Investments, LLC | 1,595,877 | +44,103 |
| FIL Ltd | 1,548,918 | +2,827 |
| UBS Group AG | 1,423,371 | -1,322,440 |
Insiders
15 insiders reported holding 6,141,540 shares in total, about $150M at the last price.
| Holder | Shares |
|---|---|
| Halbert David DSee Remarks, Director, 10% owner | 2,574,533 |
| Spetzler David BaxleyPresident | 1,182,871 |
| Halbert JonDirector | 836,411704,598 held indirectly |
| Johansen Laura IDirector | 343,897 |
| Knowles Jonathan Kenneth CharlesDirector | 308,979 |
| Brille Brian JSee Remarks, Director | 230,303 |
| Denton John RusselSee Remarks | 174,855 |
| Power Luke ThomasSee Remarks | 153,771 |
| Phillips T DannyDirector | 133,060 |
| Vacirca Jeff LDirector | 62,863 |
Questions about CAI
What does Caris Life Sciences, Inc. do?
Caris Life Sciences, Inc. is a company in the Health care sector, listed on NASDAQ as CAI. Its shares trade on NASDAQ under the ticker CAI.
What is Caris Life Sciences, Inc.'s net worth?
Caris Life Sciences, Inc. has a market value (market cap) of $6.9B at the latest share price, and shareholders' equity of $639.5M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Caris Life Sciences, Inc. profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $96.1M on revenue of $1B, a net margin of 9.2%.
How much revenue does Caris Life Sciences, Inc. make?
Over the twelve months to September 30, 2026 Caris Life Sciences, Inc. reported revenue of $1B.
When did Caris Life Sciences, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the passive stake changed from November 5, 2026.
When is Caris Life Sciences, Inc.'s next earnings report?
Caris Life Sciences, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare CAI with
Follow CAI
Get an email when Caris Life Sciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Caris Life Sciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.